Since the early 1980’s, Burkholderia cepacia is emerged as a causative agent of opportunistic human infections. Burkholderia cepacia (B. cepacia) is an opportunistic pathogen which causes severe infections in patients with underlying diseases, such as cystic fibrosis (CF) or chronic granulomatous disease (CGD). B. cepacia causes nosocomial bloodstream infections in non-CF patients with a mortality rate of 25%–64%. Several severe infections caused by B. cepacia have been reported in children e.g. sepsis, pneumonia, CNS infections, and urinary tract infections. This prospective analysis was done in tertiary care hospital in Vadodara during the period of January - June 2023. 17 non-duplicate Burkholderia cepacia were recovered from samples. Out of 17 Burkholderia cepacia isolates, 12 isolates are most sensitive to Meropenem (70.59%), Ceftazidime (52.94%), Trimethoprim/ Sulphamethoxazole (47.06%), Cefoperazone/ Sulbactam (29.41%), Imipenem (23.53%), Minocyclin (23.53%), Piperacillin/T azobactam (17.65%), Cefepime (17.65%), Ciprofloxacin (17.65%), Levofloxacin (17.65%), Aztreonam (5.88%) and, Tigecycline (0%).